Inspire Medical Systems Reports Strong Q3 2025 Growth Exceeding Revenue Expectations

Inspire Medical Systems reported strong Q3 2025 financial results, with revenue reaching $224.5 million, a 10% increase from the previous year, surpassing Wall Street estimates. The company's transition to the Inspire V system has driven global performance improvements, including a 20% reduction in surgical time and a smoother adoption in U.S. centers, contributing to enhanced sales and margins. Inspire also completed a $50 million share repurchase and raised its annual diluted net income per share guidance to $0.90-$1.00, reflecting confidence in its strategic direction. Despite higher operating expenses driven by marketing and corporate costs, Inspire maintained a robust operating cash flow of $68.5 million and demonstrated strong financial stability with a low debt-to-equity ratio and high liquidity. Investor sentiment remains positive, with analysts rating the stock as a buy and a median 12-month price target indicating significant upside potential. Overall, Inspire's innovation in minimally invasive sleep apnea treatment and consistent growth suggest sustained demand and profitability in the medtech sector.